Clinical Data
How Long Does Retatrutide Take to Work? Phase 2 Timeline & Data
Based on published Phase 2 clinical trial data (NEJM, 2023), retatrutide's effects follow a dose-dependent and time-dependent progression. This guide summarises the key findings for research context.
The landmark Phase 2 NEJM study (2023) evaluated retatrutide across multiple dose cohorts (1mg, 3mg, 4mg, 8mg, 12mg weekly) over 48 weeks in participants with obesity. The trial demonstrated dose-dependent efficacy across all primary and secondary endpoints, establishing retatrutide as the most effective GLP-1 class compound evaluated in clinical trials to date.
| Timeline | Observed Response (12mg cohort) |
|---|---|
| Week 1–2 | Appetite modulation begins — early GLP-1 and GIP receptor engagement |
| Week 4–8 | Measurable metabolic changes — energy expenditure increase from glucagon pathway |
| Week 12 | Approximately 10.4% average weight reduction observed |
| Week 24 | Approximately 17.5% average weight reduction |
| Week 48 | Average 22.5% — maximum observed in any GLP-1 class trial |
Retatrutide's triple-receptor mechanism (GLP-1 + GIP + Glucagon) accelerates the metabolic response timeline compared to single or dual agonists. The glucagon receptor component specifically increases resting energy expenditure — the rate at which the body burns calories at rest — providing an additional mechanism that semaglutide and tirzepatide lack.
| Weekly Dose | Week 24 Response | Week 48 Response |
|---|---|---|
| 1mg | ~5% | ~8% |
| 4mg | ~12% | ~17% |
| 8mg | ~15% | ~20% |
| 12mg | ~17.5% | ~22.5% |
| Compound | Mechanism | Peak Efficacy (48wk) |
|---|---|---|
| Retatrutide | Triple agonist (GLP-1/GIP/GCG) | ~22.5% |
| Tirzepatide (Mounjaro) | Dual agonist (GLP-1/GIP) | ~22% |
| Semaglutide (Wegovy) | Single agonist (GLP-1) | ~15% |
| Liraglutide (Saxenda) | Single agonist (GLP-1) | ~8% |
All data sourced from respective Phase 3 clinical trials. Figures represent average response in trial populations and are presented here for academic research context only.
Alluvi Healthcare supplies independently verified research peptides with full COA, cold chain delivery and UK-based support. Batch AR0763RT4 — 99.38% purity.